Search
Selected Filter
Displaying 11–20 of 177 research results
-
Stargardt Disease Research Advances
Recent developments in research on Stargardt disease
-
Dr. Don Zack Honored for Research Contributions by ARVO and the Foundation Fighting Blindness
Dr. Zack is a member of the Foundation’s Scientific Advisory Board and chairs its Cellular Molecular Mechanisms of Disease study section.
-
Eye Bonds provide the opportunity to advance, and accelerate development for, more promising treatments into and through clinical trials and out to the people who need them.
-
ARVO 2019: Gene Therapy Clinical Trial for RP Caused by RLBP1 Mutations Ongoing in Sweden
In a Novartis lab study, mice with RLBP1 mutations had improved dark adaptation after receiving the gene therapy. The treatment remained effective after one year.
-
ARVO 2019: Robot-Assisted Surgery in Clinical Trial for Retinal Disease
A video from a clinical trial of robot-assisted surgery demonstrates the potential benefits of robot-assisted subretinal injections.
-
ARVO 2019: Emerging Eloxx Molecules Show Promising Results in Usher Models
Eloxx Pharmaceuticals is developing small molecules that permit read-through of point mutations that cause Usher syndrome 1F and 2A.
-
ARVO 2019: Emerging Drug for RP Evaluated in Safety & Tolerability Study
Francois Paquet-Durand, PhD, chief scientific officer at the company Mireca, discusses an emerging drug for retinitis pigmentosa, and other inherited retinal diseases.
-
REGENXBIO’s Gene Therapy for Wet AMD Performing Encouragingly in Human Study
Unlike current treatments requiring multiple injections, REGENXBIO’s gene therapy is administered as a one-time subretinal injection to the affected eye.
-
ARVO 2019 Highlight: RP Patients in ReNeuron’s Cell Therapy Trial Show Further Vision Improvements
The latest ReNeuron results were presented at the sixth annual Retinal Cell and Gene Therapy Innovation Summit held on April 26 in Vancouver, Canada.
-
First Patient Receives AON Therapy for LCA10 in ProQR’s Phase 2/3 Clinical Trial
The treatment, formerly known as QR-110, is designed for people with the retinal disease Leber congenital amaurosis 10
